Work

Immunotherapy in prostate cancer: current state and future perspectives

Year: 2020

Type: review

Abstract: Metastatic castrate resistant prostate cancer (PCa) remains an incurable entity. In the era of immunotherapy, the complex PCa microenvironment poses a unique challenge to the successful application of this class of agents. However, in the last decade, a tremendous effort has been made to explore this field of therapeutics. In this review, the physiology of the cancer immunity cycle is highlighted in the context of the prostate tumor microenvironment, and the current evidence for use of various classes of immunotherapy agents including vaccines (dendritic cell based, viral vector based and DNA/mRNA based), immune checkpoint inhibitors, Chimeric antigen receptor T cell therapy, antibody-mediated radioimmunotherapy, antibody drug conjugates, and bispecific antibodies, is consolidated. Finally, the future directions for combinatorial approaches to combat PCa are discussed.

Source: Therapeutic Advances in Urology

DOI: 10.1177/1756287220951404

Authors: Shivani Handa, Bandhul Hans, Shokhi Goel, Hafis O. Bashorun, Zach Dovey, Ashutosh Tewari

Institutions: Icahn School of Medicine at Mount Sinai, Allegheny General Hospital, Mount Sinai Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,200